Ophthotech reported a net loss of $14.7 million, or $0.41 per diluted share, in 2018’s third quarter compared with a net income of $189.1 million, or $5.25 per diluted share, in the third quarter of 2017.
The end of a licensing and commercialization agreement with Novartis Pharma contributed to the company having no collaboration revenue for the quarter compared with $206.7 million in 2017’s third quarter, the company said in a press release.
General and administrative expenses decreased from $7.1 million in 2017’s third quarter to $6 million this year, (Read more...)
Uncategorized